Summary: Group key figures Q3 2025

Number of shares (as of 30.09.2025): 3,991,052 (166,626,687)

Result per share: Result for the period / weighted average number of shares

Equity ratio: Equity / Total assets

Gross Revenue: Gross Revenue refers to the total revenue generated prior to any deductions for price reductions, rebates, or returned goods from wholesalers due to product expiry.

Operational and Strategic Highlights

• The Company continues to demonstrate stable commercial traction and progress on cost optimization.
• Market conditions have stabilized following earlier volatility, allowing the Company to adapt competitively to lower market pricing and shifting demand patterns.
• While profitability has not yet been reached, initiatives are being implemented to strengthen operational efficiency and support a path toward sustainable earnings.

Financial Performance

DanCann Pharma reported net sales of DKK 1.6 million in Q3 2025, compared to DKK 1.2 million in Q2 2025 and DKK 1.9 million in Q3 2024.

This represents a +37% quarter-over-quarter (QoQ) increase and a -13% year-over-year (YoY) decline, reflecting gradual stabilization in the Danish cannabinoid prescription market after a period of price pressure and volatility earlier in the year.

EBITDA improved to -DKK 1.0 million in Q3 2025, compared to -DKK 2.2 million in Q2 2025 and -DKK 0.9 million in Q3 2024 — corresponding to a 53% improvement QoQ, supported by continued cost optimization and operational discipline.

Operating profit (EBIT) followed a similar trend, improving from -DKK 2.7 million in Q2 2025 to -DKK 1.5 million in Q3 2025, indicating sequential progress in terms of performance.

Leadership Transition

During the quarter, founder and long-standing CEO, Mr. Jeppe Krog Rasmussen, stepped down from his executive position to pursue new professional opportunities. Under his leadership, DanCann Pharma successfully navigated its formative years, obtained regulatory approvals, and established itself as a trusted operator within the regulated medicinal cannabis sector.

To ensure continuity, Chairman of the Board, Mr. Carsten Trads, has assumed the role of Interim Chief Executive Officer, with a transition plan in place to appoint Mr. Peter Hauberg Søndergaard, previously Chief Financial Officer, as the new CEO in the coming months. Peter brings a strong financial background and operational discipline, and will lead the execution of DanCann Pharma’s long-term strategy, Maturity2028, with a focus on capital efficiency, profitability, and value creation.

Delisting and Continued Share Trading

Following shareholder approval at the Extraordinary General Meeting on 21 October 2025, the Company will proceed with a voluntary delisting from Spotlight Stock Market. The last expected trading day is 22 January 2026.

To ensure transparency and maintain trading flexibility for shareholders after delisting, DanCann Pharma will establish a dedicated section on its corporate website to facilitate over-the-counter (OTC) trading between interested buyers and sellers. The platform will include step-by-step guidance on share registration and trading procedures to support investors post-delisting.

Looking Ahead

Interim CEO & Chairman Carsten Trads commented:

“The third quarter has been transformative for DanCann Pharma. While market volatility continues to influence results, the Company remains steadfast in executing its strategic roadmap. With leadership transition well underway, the divestment of BP1 progressing, and preparations for the delisting complete, DanCann Pharma is entering a new chapter focused on profitability, capital efficiency, and long-term value creation.”

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

DanCann Pharma A/S

Rugvænget 5, DK-6823 Ansager, Denmark

E-mail: info@dancann.com

Website: www.dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-10-2025.